Probiodrug reports financial results for H1 2017 and corporate update
Probiodrug initiates Phase 2b core program of PQ912 and details further strategy
Probiodrug reports financial results for H1 2017 and corporate update
Probiodrug initiates Phase 2b core program of PQ912 and details further strategy
HALLE (SAALE), Germany, 28 September 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is scheduled to attend the following conferences:
(1) EU Neurotech Investing and Partnering
03-04 October 2017, The Wyss Center, Geneva, Switzerland
Dr Hendrik Liebers, CFO, to host meetings and participate on Tuesday, 3 October 2017 at 10:45 am CEST, at the panel “Treatment for Alzheimer’s and Cognitive Disorders”
(2) European Large & Midcap Event
04-05 October 2017, Palais Brongniart, Paris, France
Dr Hendrik Liebers, CFO, to host meetings
11 October 2017, Harvard Medical School – Joseph B. Martin Conference Center, Boston, USA
Dr Konrad Glund, CEO, to host meetings and participate on Wednesday, 11 October 2017 at 10:30 am EST, at the panel “Partnering in Neuroscience”
17-18 October 2017, Westin St. Francis Hotel, San Francisco, USA
Dr Hendrik Liebers, CFO, to host meetings and present on Tuesday, 17 October 2017 at 3:30 pm PST, at Room Elizabethan C
(5) Sofinnova Japan Biopharma Partnering Conference
24 October 2017, The Conrad Hotel, Tokyo, Japan
Dr Hendrik Liebers, CFO, to host meetings and present on Tuesday, 24 October 2017 at 11:35 am JST
###
For more information, please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume Brophy
Conor Griffin, Alexander Protsenko, Jonothan Blackbourn
Tel: +44 (0) 20 7862 6381
Email: probiodrug@humebrophy.com
The Trout Group
Tricia Truehart, Kelly Mueller
Tel: +1 (646) 378-2953
Email: ttruehart@troutgroup.com
MC Services AG
Anne Hennecke, Caroline Bergmann
Tel: +49 (0) 211 529 252 20
Email: probiodrug@mc-services.eu
Notes to Editors:
About Probiodrug AG
Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease (AD). Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting a key neuro/synaptotoxic component of the pathology, pyroglutamate-Abeta (pGlu-Abeta, N3pG) as a therapeutic strategy.
Pobiodrug’s lead product candidate, PQ912, is a highly specific and potent inhibitor of Glutaminyl Cyclase (QC), which has shown therapeutic effects in AD animal models. A Phase 1 study with healthy young and elderly volunteers revealed a dose dependent exposure and showed good safety and tolerability up to the highest dose showing >90% target occupancy in the spinal fluid. In June 2017 Probiodrug announced top-line data of the Phase 2a SAPHIR trial of its lead candidate (Probiodrug announces encouraging results of the Phase 2a SAPHIR Study ). The positive effects seen on secondary exploratory efficacy markers are strongly supporting (a) the hypothesis of pGlu-Abeta being synaptotoxic and (b) the therapeutic concept pursued by Probiodrug. The study revealed a positive benefit risk ratio of PQ912 and provides important guidance how to move forward in the development of PQ912 as a disease-modifying drug for AD. Altogether, the results make the program highly attractive for further development.
Complementary to the small molecule PQ912 inhibiting the formation of the synaptotoxic agent pGlu-Abeta, the company is developing PBD-C06, an anti-pGlu-Abeta-specific monoclonal antibody.
The Company has medical use and composition of matter patents related to the inhibition of QC and anti‑pGlu‑Abeta-specific monoclonal antibodies, and has, in the Company’s view, a leading position in this field of research.
Founded in 1997 by Hans-Ulrich Demuth and Konrad Glund, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today, Probiodrug aims to become a leading company in the development of AD treatments and to thereby provide a better life for Alzheimer’s disease patients.
About Alzheimer’s disease
Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 47 million people live with dementia worldwide, and this number is projected to treble to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. Alzheimer’s has an estimated, global societal cost of US$ 818 billion, and it will become a trillion dollar disease by 2018. (World Alzheimer Report 2016).
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.